Date: Wednesday, February 28, 2018
Time:11:00 am ET / 8:00 am PT / 4:00 pm GMT
Early stages of drug development programs are designed to be lean and fast paced. The diminishing return on investment facing the pharmaceutical industry applies additional downward pressure even at the early stages to select the best molecules to advance into the clinic phases as quickly and efficiently as possible. Larger pharmaceutical companies have the resources and expertise to screen dozens of molecules in late stage preclinical studies and allow for attrition for molecules. Small biotech companies lack the resources, API quantities, and expertise to allow for such attrition and only a few molecules may anchor an entire program. In either case, scientists need to implement strategies to fully characterize and assess molecule developability, enhance the solid state chemistry of API, and apply necessary solubility enhancing technologies.
Lipid based drug delivery systems (LBDDS) are the most studied and understood bioavailability enhancing solutions and have been used to deliver more than 60 new drug molecules to the global market. The versatility and range of LBDDS are customizable to meet the demands of increasingly poorly soluble drug candidates. In addition to addressing a molecule's physicochemical characteristics, LBDDS screening is fast, simple in the preclinical setting, and its scalability is relatively straightforward.
Key Learning Objectives:
- Understand the importance of preformulation characterization to improve small molecule drug developability;
- Learn how LBDDS can be used for preclinical formulation screening;
- Understand the advantages of using LBDDS to overcome physicochemical and biopharmaceutical challenges;
- Learn how to select the best drug candidate and drug formulation for animal studies.
Sr. Manager, Product Development
Catalent Pharma Solutions
Global Head of Chemical and Pharmaceutical Profiling
Novartis Institutes for BioMedical Research